Common therapeutic targets in cardiometabolic disease.

Abstract

The interactions between cardiovascular disease (CVD) and insulin resistance syndromes suggest the possibility of joint targets for cardiometabolic research. The best drugs would go beyond minimizing adverse effects and have protective actions against both metabolic disease and CVD. In this perspective, we will outline a few examples in which a deep mechanistic understanding of the many cellular pathways that contribute to type 2 diabetes and CVD, regardless of cell type, have resulted in common upstream pathogenic pathways that can be therapeutically targeted.